摘要
目的了解急性白血病(AL)病人凝血酶激活纤溶抑制物(TAFI)活性水平的变化。方法应用发色底物法检测50例AL病人及30例正常人的TAFI活性水平,并进行统计学比较。结果AL病人治疗前TAFI:A为2.55±0.84μg/ml,较正常对照组的7.22±2.22μg/ml显著降低(P<0.01)。急性早幼粒细胞白血病(APL)病人TAFI:A为1.50±0.14μg/ml显著低于其它类型AL(P<0.05)。结论AL病人凝血酶激活的纤溶抑制物(TAFI)活性降低,以APL病人表现更显著,但其可随病情好转而逐渐改善。
Objective To explore the significance in the clinical therapy of acute leukemia（AL）. Methods 50 AL patients were selected into the study. The levels of thrombin- activatable fibrinolysis inhibitor ：A were measured by chromogenic assay. Meanwhile,the AL patients were measured before and after therapy. Resuits Compared with normal group,plasma levels of thrombin- activatable fibrinolysis inhibitor： A were degraded before treatment in AL patients （P 〈 O. 01 ）. Plasma levels of thrombin-activatable fibrinolysis inhibitor ： A in APL were lower than the other type of acute leukemia. Conclusion Fibrinolysis existed in AL patients and the decrease of anti- fibrinolysis maybe the main reason of hemorrhage, plasma levels of thrombin- aetivatable fibrinolysis inhibitor ： A were more lower than the other type of AL. After treatment, plasma levels of thromhin-activatable fibrinolysis inhibitor ：A came to recovery.
出处
《血栓与止血学》
2008年第5期213-215,共3页
Chinese Journal of Thrombosis and Hemostasis
基金
基金项目:桂科教研[2003]22号文第9号
关键词
急性白血病
凝血酶激活纤溶抑制物
Acute leukemia
Thrombin-activatable fibrinolysis inhibitor
